4//SEC Filing
Cormorant Asset Management, LP 4
Accession 0000929638-25-001870
CIK 0001637715other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:36 PM ET
Size
14.5 KB
Accession
0000929638-25-001870
Insider Transaction Report
Form 4
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Cormorant Asset Management, LLC
10% Owner
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Chen Bihua
10% Owner
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Transactions
- Sale
Class A Common Stock
2025-05-12$1.99/sh−24,300$48,236→ 1,813,439 total(indirect: See Footnotes)
Footnotes (3)
- [F1]Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP.
- [F2]Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- [F3]Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V.
Documents
Issuer
OnKure Therapeutics, Inc.
CIK 0001637715
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001583977
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:36 PM ET
- Size
- 14.5 KB